Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia

European Neuropsychopharmacology

Volumn 24, Issue 2, 2014, Pages 215-222

  Brain, Cecilia ^a,b   Sameby, Birgitta ^b   Allerby, Katarina ^b   Lindström, Eva ^c   Eberhard, Jonas ^d   Burns, Tom ^e   Waern, Margda ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adherence; Antipsychotics; Medication Event Monitoring System; Pill count; Plasma levels; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTPATIENT; PATIENT COMPLIANCE; PILL; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; YOUNG ADULT;

ADHERENCE; ANTIPSYCHOTICS; MEDICATION EVENT MONITORING SYSTEM; PILL COUNT; PLASMA LEVELS; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SCHIZOPHRENIA; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 84893687136     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.11.013     Document Type: Article

References (35)

1. Ascher-Svanum H., Zhu B., Faries D., Lacro J.P., Dolder C.R. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J. Clin. Psychiatry 2006, 67:1114-1123.
2. ® in the Swedish COAST-study. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 2013, 23:1754-1762.
3. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B., Rush A.J. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005, 133:129-133.
4. Chen A. Noncompliance in community psychiatry: a review of clinical interventions. Hosp. Community Psychiatry 1991, 42:282-287.
5. Cooper D., Moisan J., Gregoire J.P. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J. Clin. Psychiatry 2007, 68:818-825.
6. Cramer J.A., Rosenheck R. Enhancing medication compliance for people with serious mental illness. J. Nerv. Ment. Dis. 1999, 187:53-55.
7. Diaz E., Levine H.B., Sullivan M.C., Sernyak M.J., Hawkins K.A., Cramer J.A., Woods S.W. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J. Psychiatry Neurosci. 2001, 26:325.
8. Dolder C.R., Lacro J.P., Dunn L.B., Jeste D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry 2002, 159:103-108.
9. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33:766-771.
10. Farmer K.C. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin. Ther. 1999, 21:1074-1090. (discussion 1073).
11. Goff D.C., Hill M., Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2010, 71(Suppl 2):20-26.
12. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. In: US Department of Health Education, a.W., Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville. (Ed.).
13. Hudson T.J., Owen R.R., Thrush C.R., Armitage T.L., Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J. Clin. Psychiatry 2008, 69:74-80.
14. Kane J.M., Kishimoto T., Correll C.U. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry: Off. J.World Psychiatr. Assoc. 2013, 12:216-226.
15. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
16. Kinon B.J., Hill A.L., Liu H., Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int. J. Neuropsychopharmacol. 2003, 6:97-102.
17. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63:892-909.
18. Lindstrom E., Eriksson L., Levander S. Suicides during 7 years among a catchment area cohort of patients with psychoses. Nord. J. Psychiatry 2012, 66:8-13.
19. Nakonezny P.A., Byerly M.J., Rush A.J. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res. 2008, 157:259-263.
20. Novick D., Haro J.M., Suarez D., Perez V., Dittmann R.W., Haddad P.M. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010, 176:109-113.
21. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 2002, 63:1121-1128.
22. ®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr. Res. 2007, 90:229-237.
23. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56:241-247.
24. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011, 168:603-609.
25. Tsang H.W.H., Fung K.M.T., Corrigan P.W. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia. J. Behav. Ther. Exp. Psychiatry 2009, 40:3-14.
26. Valenstein M., Ganoczy D., McCarthy J.F., Myra Kim H., Lee T.A., Blow F.C. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J. Clin. Psychiatry 2006, 67:1542-1550.
27. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
28. Velligan D.I., Lam F., Ereshefsky L., Miller A.L. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr. Serv. 2003, 54:665-667.
29. Velligan D.I., Lam Y.W.F., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr. Bull. 2006, 32:724-742.
30. Velligan D.I., Wang M., Diamond P., Glahn D.C., Castillo D., Bendle S., Lam Y.W., Ereshefsky L., Miller A.L. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 2007, 58:1187-1192.
31. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl 4):1-46. (quiz 47-48).
32. Weiden P., Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr. Q. 1997, 68:377-392.
33. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 2004, 55:886-891.
34. Yang J., Ko Y.-H., Paik J.-W., Lee M.-S., Han C., Joe S.-H., Jung I.-K., Jung H.-G., Kim S.-H. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr. Res. 2012, 134:226-231.
35. Zygmunt A., Olfson M., Boyer C.A., Mechanic D. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry 2002, 159:1653-1664.